

1  
2  
3 **Examining our laboratory results through participation in**  
4 **multinational material exchange studies**  
5  
6  
7

8 **ABSTRACT**

9 **Aim:** The aim of this study is to determine the quality of our tissue processing through participation a  
10 multicentre research programme as part of external quality control.

11 **Study Design:** A analytical retrospective study.

12 **Place and Duration of Study:** Department of Pathology University of Calabar Teaching Hospital, July  
13 2019.

14 **Methodology:**An analytical study reviewing the performance of lymphoma tissue contributed to a Sub-  
15 Saharan African Lymphoma consortium study commissioned in 2008/2009 for which results were  
16 published in 2012. Twelve formalin fixed paraffin embedded lymphoma tissue were tested with a panel of  
17 40 immunohistochemistry antibodies. The tissues were cut into 480 cores placed on slides before the  
18 test.

19 **Results:** The tissues were from 5 women and 7 men. The mean age was 37years, median age 45 years  
20 and modal age was 60 years.Twenty six percent of the sectioned cores lifted at test an could not  
21 therefore produce results.The reason for the lift off was tissue brittleness. Seventy four percent (74%) had  
22 intact cores on slides and produced a staining reaction although fragile antibodies like Ki 67 and bcl6  
23 produced non reliable results while hardy antibodies like CD20 were more reliable.

24 **CONCLUSION:**The quality of histopathology biopsy results in the Department of Pathology University of  
25 Calabar teaching hospital needs to be improved. The strategies to achieve this involves the institution of  
26 continuous quality control and quality assurance.

27 **Keywords:** *Quality control, quality assurance, Calabar*

28 **INTRODUCTION:** Approaches to instituting quality control (QC) and quality assurance (QA) in  
29 Anatomic pathology may vary, but the result is the same. A laboratory for instance set up its QC  
30 committee with a mandate to assess two levels of QC, these are external quality control(EQA) and  
31 internal quality control (IQC)(1).IQC involved inter and intradepartmental seminars to improve the  
32 process, turnaround time, monitoring errors and troubleshooting on abnormal occurrences. EQA activities  
33 involve participation in external proficiency activities as well as bench marking with remote centres(1).In  
34 America the association of Anatomic directors published three articles on quality control; these have  
35 shaped quality management in Anatomic pathology(2). The first is concerned with internal quality  
36 assurance which emphasizes turnaround time and reliability of the diagnosis(2). The second article was  
37 concerned with the standardization of the pathology report. The third article was centred on the  
38 standardization of the consultation in Anatomic pathology(2).


39 An erroneous laboratory result exposes a patient to harm(3).Quality assurance activities must address  
40 the three phases of the histopathological test cycle; these are the preanalytical, analytical, and post  
41 analytical(4). The preanalytical phase, is said to account for most of the errors(4-6), this why it is often  
42 taken seriously in the laboratory(7, 8).Subjectivity in histopathology and cytopathology reports makes  
43 instituting QC in these test difficult. To overcome this shortcoming, the bulk of laboratory QC activities  
44 centre on internal quality control.(9, 10).In large laboratories, it may be technically impossible to peer

45 review all results issued .An ingenious way one laboratory set out its QC was to set up an internal QC  
46 committee and peer review mechanism which selects through systematic random sampling 10% of the  
47 previous week reports for review(10).The peer review led to comments to be made on made 19.6% of the  
48 results(10). Comments which range from microscopic description(4%) through macroscopic description  
49 (3.1%),to 0.3 % incorrect results, examined all aspect of the test process(10).They summarized the  
50 positive outcome of instituting IQC to include:1 Stimulus at both conscious and subconscious level to be  
51 always accurate;2 more frequent case consultation among pathologists;3 uniformity in diagnostic  
52 terminology, grading system and criteria among Pathologists;4 feed back to the scientific and technical  
53 staff in terms of the technical quality and productivity of the department, among others(10).

54 We present a snapshot review of an earlier participation in a multicentre lymphoma study, by evaluating  
55 the performance of our histology blocks as an external quality control for tissue biopsy. The focus of the  
56 laboratory is to establish an enduring quality management system. In the next articles we shall examine  
57 several aspects of internal quality controls as they exist before we institute a more robust quality  
58 management.

59 **MATERIALS AND METHODS:** A retrospective study of the performance of randomly selected  
60 formalin fixed paraffin embedded (FFPE) lymphoma tissue contributed to a Sub Saharan Africa  
61 lymphoma consortium study was carried out. Sixteen (16) FFPE tissue blocks from 14 lymphoma cases  
62 were contributed. Of the FFPE blocks selected two (2) were from 2007 collection, three from 2008  
63 collection and the rest from 2009 collection. Four of the FFPE blocks from two patients diagnosed as  
64 human immunodeficiency virus (HIV)associated lymphoma followed a different analysis pathway and thus  
65 excluded from the study. The remaining 12 FFPE blocks were subjected to immunohistochemistry  
66 analysis and cores were taken for tissue microarray analysis. Those treated to immunohistochemistry  
67 analysis are included in the study while the tissue microarray processed cores are excluded from this  
68 study. The tissues were subjected to a panel of 40 antibodies. Feedback was sent to us as hard copies  
69 and electronic copies and comprised of general comments and results of immunohistochemical analysis.  
70 The data is fed into excel Microsoft statistical package for analysis.

71 **RESULTS:** Twelve FFPE lymphoma tissue from 5 females and 7 males were analysed. This is  
72 represented in a bar chart in figure 1.



73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85 **Figure 1. Bar Chart Showing the Sex Distribution of Patients from Whom FFPE Were Selected for**  
86 **Study**

87

88 **Table 1. The Age Distribution of Patients in the Study**

89

90

Age groups	Frequency	Percentages
<21	5	42
21-30	0	0
31-40	1	8
41-50	1	8
51-60	4	34
61-70	1	8
Total	12	100

91

92

93

94

95


96

97

98 The youngest patient was 3 years and the oldest 70 years, the range being 3 -70 years. This is  
99 represented in table 1 and the bar chart in figure 2. The mean age of patients was 37, median age was 45  
100 and modal age was 60 years.

101

102



116 **Figure 2. Bar Chart Showing the Age Distribution of Patients**

117 The EQA statement was that our tissues were not optimally fixed, and the ideal fixative neutral buffered  
118 formalin was not used. The unbuffered fixative employed in our centre is usually acidic and may have  
119 affected the antigen recovery in immunohistochemistry. That processing may have distorted the cellular  
120 morphology and the tissue fragility resulted in lack of adhesiveness to the glass slide. The  
121 immunohistochemistry result was affected by the acidic formalin with less avid antibodies such as Ki67  
122 and bcl16 staining poorly while CD20 staining was more reliable. The morphologic diagnosis from our  
123 centre was judged to be good.

124 A total of 40 antibody panels employed in lymphoma diagnosis were tested for each of the 12 lymphoma  
125 patients and this amounted to a total of 480 cells. Brittle tissue sections did not adhere to the glass slide  
126 and were marked as no core NC and therefore no staining reaction was expected in such cells. The total  
127 number of NC recorded was 132.

128


129 **Table 2. Distribution of Cores**

130

TOTAL NO OF CORES THAT FELL OFF (NC)	TOTAL NO OF INTACT CORES	TOTAL NO OF CORES
132	384	480

133

134



147 **Figure 3. Bar diagram showing the behaviour of cores**

148

149

150

151

152


153

154

155

156

157



170 **Figure 4. Graphical representation of core distribution**

171  
172

173 **DISCUSSION:** The performance of our tissue in this unintended EQA was an eye opener and opens the  
 174 door for necessary improvement in our quality. A 26% fall off rate in our tissue cores in  
 175 immunohistochemisistry is undesirable. The initial handling of a tissue in histopathology from the  
 176 preanalytical phase to the analytic phase is of utmost importance(4, 5, 11). Very often following the basic  
 177 analysis with Haematoxylin and eosin staining, the tissue is then subjected to complex array of  
 178 test which may determine the type of therapeutic intervention and ultimately the prognosis. If the tissue  
 179 had been man handled the information could be lost and the patient the worse for it.The need for  
 180 pathological diagnosis is increasing as non-communicable diseases increase in the developing world  
 181 especially(12). The laboratories must brace up for this challenge by providing quality test results(12).

182 Robust internal quality assurance measures will need to be put in place in our laboratory to improve the  
 183 quality of our laboratory results. This requires extreme commitment of time and resources, but this must  
 184 be done for the sake of our patients. The method of continuous internal quality assurance which seeks to  
 185 review 10% of the test result at every step of the test process seems the most feasible to adopt(10, 11,  
 186 13-15).In this cost conscious era and so as to satisfy accreditation bodies that are beginning to ask  
 187 questions the institution of QC and QA is the way forward(1, 16, 17).Just as College of American  
 188 Pathologist has driven QC and QA (18, 19), in Nigeria College of Nigerian Pathologist and the Federal  
 189 ministry of health are beginning to drive the process. In conclusion, a good laboratory test result must be  
 190 accurate, timely, reliable and must satisfy the client. It does appear that until we improve our process the  
 191 test results are not very reliable.

192 **CONCLUSION:**The quality of histopathology biopsy reports from our department needs improvement.  
 193 This can be achieved through the institution of continuous internal quality control and other quality  
 194 assurance measures.

195 **RECOMMENDATIONS.**The recommendation of the author is the immediate institution of continuous  
 196 internal quality control, as well as external quality control participation.Management of the hospital and  
 197 laboratory should support the laboratory with resources to enable it achieve these goals.

198 **COMPETING INTEREST:** The author declares no competing interest.

199 **CONSENT:**No consent was required for this work.

200 **ETHICAL APPROVAL:**Ethical approval was granted by the institutional ethical review board.

201

202 **REFERENCES:**

- 203 1. Alampi G, Baroni R, Berti E, Ceccarelli C, Dina R, Eusebi V, et al. [Quality control at the Istituto  
204 Anatomia e Istologia patologica at the Universita di Bologna]. *Pathologica*. 1994;86(2):184-90.
- 205 2. Namiki T. [Quality assurance of pathology laboratory, standardization of surgical pathology report  
206 and consultation: recent trend]. *Rinsho Byori*. 1994;42(9):897-901.
- 207 3. Parvin CA, Baumann NA. Assessing Quality Control Strategies for HbA1c Measurements From a  
208 Patient Risk Perspective. *J Diabetes Sci Technol*. 2018;12(4):786-91.
- 209 4. Rao S, Masilamani S, Sundaram S, Duvuru P, Swaminathan R. Quality Measures in Pre-Analytic  
210 of Tissue Processing: Understanding Its Value in Histopathology. *J Clin Diagn Res*.  
211 2016;10(1):EC07-11.
- 212 5. Errors in a Stat Laboratory: Types and Frequencies 10 Years Later *Clinical Chemistry*. 2007; 53  
213 (7):1338–42.
- 214 6. Robert Hawkins MD. Managing the Pre- and Post-analytical Phases of the Total Testing Process.  
215 *Ann Lab Med*. 2012;32::5-16
- 216 7. Muhammad Ashraf Sharif SM, Nadira Mamoon<sup>3</sup>, Shahid Jamal<sup>4</sup>, Muhammad Luqman<sup>5</sup>.  
217 CLINICIAN'S RESPONSIBILITY IN PRE-ANALYTICAL QUALITY ASSURANCE OF  
218 HISTOPATHOLOGY *Pak J Med Sci (Part-I)* 2007; Vol. 23 ( No. 5 ):720-3.
- 219 8. Zubair Ahmad RI, Nasir Uddin, Arsalan Ahmed, Saira Fatima. Errors in Surgical Pathology  
220 Reports: a Study from a Major Center in Pakistan *Asian Pac J Cancer Prev*, . 2016; 17 ((4),):  
221 1869-74.
- 222 9. Cardoso Filho LI, Tavares SBN, Siqueira MLB, Dos Passos EN, Araujo N, Martins JMA, et al.  
223 Internal quality control indicators in cervical cytopathology of a university laboratory.  
224 *Cytopathology*. 2018;29(4):355-60.
- 225 10. Ibrahim M Zardawi GB, Sanjiv Jain, Michael Brown. Internal quality assurance activities of a  
226 surgical pathology department in an Australian teaching hospital. *J Clin Pathol* 1998;51:695-9.
- 227 11. Dr.Aarti B .Bhattacharya DSB, Dr.Rumpa Das , Dr.Priyankar Sharma Dr. Shashwat Vidyadhar  
228 An audit of diagnostic surgical pathology: A tool for quality assurance. Original study in a rural  
229 teaching hospital in Eastern Uttar Pradesh, India *IOSR Journal of Dental and Medical Sciences*  
230 (IOSR-JDMS) (May. 2015),;Volume 14,( Issue 5 Ver. III): PP 32-3
- 231 12. Fleming KA, Naidoo M, Wilson M, Flanigan J, Horton S, Kuti M, et al. High-Quality Diagnosis: An  
232 Essential Pathology Package, In: rd, Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R,  
233 et al., editors. *Disease Control Priorities: Improving Health and Reducing Poverty*. Washington  
234 (DC)2017.
- 235 13. Rickert RR. Quality assurance in anatomic pathology. *Clin Lab Med*. 1986;6(4):697-706.
- 236 14. Cowan DF. Quality assurance in anatomic pathology. An information system approach. *Arch*  
237 *Pathol Lab Med*. 1990;114(2):129-34.
- 238 15. Collina G, Caprara G, Di Tommaso L. [Quality control in pathological anatomy: 10 years'  
239 experience]. *Pathologica*. 2003;95(4):171-8.
- 240 16. Zarbo RJ. Quality assessment in anatomic pathology in the cost-conscious era. *Am J Clin Pathol*.  
241 1996;106(4 Suppl 1):S3-10.
- 242 17. Pai S, Frater JL. Quality management and accreditation in laboratory hematology: Perspectives  
243 from India. *Int J Lab Hematol*. 2019;41 Suppl 1:177-83.
- 244 18. Kraemer BB. Quality assurance activities of the College of American Pathologists. *Acta Cytol*.  
245 1989;33(4):434-8.
- 246 19. Bachner P, Howanitz PJ, Lent RW. Quality improvement practices in clinical and anatomic  
247 pathology services. A College of American Pathologists Q-probes study of the program  
248 characteristics and performance in 580 institutions. *Am J Clin Pathol*. 1994;102(5):567-71.

249